The Seventeenth Annual Pharmaceutical and Medical Device Compliance Congress will be meeting October 19, 2016 through October 21, 2016, at the Mandarin Oriental in Washington, D.C.
This year’s Pharma Congress boasts several keynote speakers, including Thomas W. Abrams, RPh, MBA, Director of the Office of Prescription Drug Promotion at the Food and Drug Administration; Joseph Beemsterboer, JD, the Deputy Chief of the Health Care Fraud Unit in the Criminal Division of the U.S. Department of Justice; Sophie Peresson, LLM, MA, Director of Pharmaceuticals and Healthcare Programme at Transparency International UK; and Mary E. Riordan, Esq., the Senior Counsel at the Office of Counsel to the Inspector General, Office of Inspector General, U.S. Department of Health and Human Services.
October 19, 2016
The morning of Wednesday, October 19, begins with three different choices for preconference symposia: Managed Markets 101, Being Prepared for External Investigations, and Advanced Global Compliance Issues. The afternoon starts off with a welcome and introduction, followed by an overview of the pharmaceutical marketplace and politics in the United States.
The afternoon then continues with a Chief Compliance Officer Roundtable, promising viewpoints from a handful of compliance officers on how to handle hot-button issues; a Keynote Annual OIG Update presented by Mary Riordan, Senior Counsel of the Office of Counsel to the Inspector General at HHS; the Annual AUSA Roundtable; and Annual FDA-OPDP Update. Day One ends with a networking reception.
October 20, 2016
The second day of the Congress opens with a keynote speech from Sophie Peresson of Transparency International, followed by a discussion entitled, “Behind the Bribe: Multiple Real-World Perspectives on How Foreign Bribery Occurs, Is Investigated, and Could Be Prevented,” with perspectives from both the government side and private practice being presented.
The schedule then breaks out into mini summits, with a variety of topics such as: Compliance Considerations for the Managed Markets Business, New Ethics-Based Approaches to Policies; Enhancing Third Party Oversight and Due Diligence; Leveraging Publically Available Data: Taking Open Payment Data A Step Further; Compliance 2.0: Shared Ownership of Effective Compliance Across Business Functions; Managed Markets Risk Assessment and Monitoring; Advanced Compliance Issues for Medical Devices: Working Through Distributors; and Evolution of Risk Assessment and Management Programs.
Day Two Closes out with several other panels, including a panel on how to drive the evolution of compliance programs into systems that support business integrity; and one on recent developments in executive liability cases: Vascular Solutions, Warner Chilcott, and Acclarent.
October 21, 2016
Once again, the third day of the Congress is a closed session, open only to pharmaceutical company ethics and compliance professionals, and in-house counsel. Attendance is limited to those invitees only so as to permit attendees to engage in a more focused exchange of views regarding issue priority and best compliance practices.
Registration
This year, attendees will have the option of either attending the conference in-person on site or attending from your home or office via the internet. If you are interested in attending the Congress, you can register here. If you register by September 9, 2016, you can save up to $400 (no code required).